A Promising Potential Drug Target: KIR3DX1 and Its Potential Applications

Target Name: KIR3DX1

NCBI ID: G90011

KIR3DX1

Other Name(s): killer cell immunoglobulin like receptor, three Ig domains X1 (pseudogene) | LENG12 | KIR3DL0 | Killer cell immunoglobulin like receptor, three Ig domains X1 (pseudogene), transcript variant 1 | KIR3DX1 variant 1

A Promising Potential Drug Target: KIR3DX1 and Its Potential Applications

The immune system is a critical component of our bodies, which defends us against infections, viruses, and diseases. The killing cell immunoglobulin like receptor (KIR) is a protein that plays a vital role in the immune response. KIR is a family of transmembrane proteins that belong to the immunoglobulin superfamily. KIR has three Ig domains, X1 (pseudogene), which are responsible for recognizing and activating antigens.

Recent studies have identified KIR as a potential drug target in various diseases, including cancer, autoimmune disorders, and inflammatory diseases. In this article, we will explore the details of KIR3DX1, a KIR gene that has shown promising potential as a drug target.

The KIR3DX1 Gene

KIR3DX1 is a gene that encodes a protein with four extracellular domains: a constant region, a variable region, a hinge region, and a C-terminal hypervariable region (HVR). The KIR3DX1 gene is located on chromosome 19 at position 362.3.

Function of KIR3DX1

KIR3DX1 is a type-I transmembrane protein that contains three Ig domains (X1, X2, and X3) and a variable region. The X1 domain is responsible for the recognition of the antigens, while the X2 and X3 domains are involved in the regulation of the immune response.

KIR3DX1 has been shown to play a crucial role in the regulation of cell proliferation and differentiation. It has been shown to be involved in various cellular processes, including cell adhesion, migration, and survival.

KIR3DX1 as a Drug Target

Recent studies have suggested that KIR3DX1 may be a potential drug target due to its unique structure and its involvement in various cellular processes. One of the main reasons for its potential as a drug target is its unique structure, which allows for the production of specific and efficient antibodies.

KIR3DX1 has been shown to be a good candidate for monoclonal antibodies ( monos), which are antibodies produced by a single cell. Monos have the potential to be more effective than polyclonal antibodies, which are antibodies produced by multiple cells.

Another reason for the potential of KIR3DX1 as a drug target is its involvement in various cellular processes that are associated with cancer and other diseases. For instance, KIR3DX1 has been shown to be involved in the regulation of cell apoptosis, which is the process by which cells die naturally.

KIR3DX1 has also been shown to be involved in the regulation of cell signaling pathways, which are important for various cellular processes, including cell growth, differentiation, and survival.

Potential Applications

KIR3DX1 has shown promising potential as a drug target due to its unique structure and its involvement in various cellular processes that are associated with cancer and other diseases.

One of the main potential applications of KIR3DX1 as a drug target is its involvement in the regulation of cell apoptosis. Researchers have shown that KIR3DX1 plays a role in the regulation of cell apoptosis by promoting the production of pro-apoptotic transcription factors.

Another potential application of KIR3DX1 as a drug target is its involvement in the regulation of cell signaling pathways. KIR3DX1 has been shown to be involved in the regulation of several signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

KIR3DX1 has also been shown to be involved in the regulation of

Protein Name: Killer Cell Immunoglobulin Like Receptor, Three Ig Domains X1 (pseudogene)

The "KIR3DX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIR3DX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets